"1+8+N"布局稳定推进，全球医疗服务网络持续完善上半年公司"1+8+N"战略取得实质进展，长沙爱 尔、上海爱尔、广州爱尔、四川爱尔、重庆爱尔、湖北爱尔、辽宁爱尔、深圳滨海爱尔等眼科中心已运 营，北京项目正在建设中。截至2025 年6 月30 日，公司境内医院355 家，门诊部240 家。截至2025 年6 月30 日，境外已布局169 家眼科中心及诊所，逐渐形成覆盖全球的医疗服务网络。通过主办第19 届世 界近视眼大会及第18 届世界眼科医院协会年会，进一步提升国际品牌影响力。 投资建议 H1 费用率呈下降态势，营业成本上升拖累毛利率根据Wind 数据，2025 年H1 公司销售费用率9.15%， 同比下降1.47 pct，管理费用率为14.89%，同比下降0.04 pct，财务费用率0.42%，同比下降0.57 pct，研 发费用率1.35%，同比下降0.06 pct。2025H1 公司毛利率48.56%，较上年同期下降0.88 pct，净利率 19.29%，同比下降1.66 pct。 门诊量增长明显，核心业务稳健 根据公司半年报，2025H1 现门诊量924.83 万人次，同比增长16.47%；手术量 ...

Group 1 - The company reported a revenue of 2.678 billion yuan in 2024, a year-on-year decrease of 1.46%, and a net profit attributable to shareholders of -102 million yuan, a decline of 138.02% [1] - In Q1 2025, the company achieved a revenue of 742 million yuan, a year-on-year increase of 9.82%, and a net profit attributable to shareholders of 27 million yuan, a growth of 61.18% [1] - The company expects a recovery in 2025, driven by improved consumer environment and policy support [2] Group 2 - In 2024, the company's revenue from refractive projects was 1.227 billion yuan, down 5.31% year-on-year, while cataract project revenue was 576 million yuan, down 3.04% [2] - The gross margin for refractive projects in 2024 was 47.02%, a decrease of 4.56 percentage points compared to the same period in 2023 [2] - The overall gross margin in 2024 was 36.98%, down 7.02 percentage points year-on-year, with a net margin of -3.47%, a decline of 13.7 percentage points [3] Group 3 - The company anticipates net profits of 118 million yuan, 197 million yuan, and 255 million yuan for the years 2025, 2026, and 2027 respectively, reflecting adjustments due to factors like artificial crystal procurement and DRG policy [4] - The company is positioned as a leading private ophthalmology medical enterprise in China, with clear expansion plans in provincial capitals [4] - The aging population is expected to drive demand for medical services, supporting the company's growth trajectory [4]

Core Insights - The company reported a revenue of 20.983 billion yuan for 2024, a year-on-year increase of 3.02%, and a net profit attributable to shareholders of 3.556 billion yuan, up 5.87% [1] - In Q1 2025, the company achieved a revenue of 6.026 billion yuan, representing a year-on-year growth of 15.97%, and a net profit of 1.050 billion yuan, an increase of 16.71% [1] - The company demonstrated strong operational resilience despite a slowdown in the ophthalmology industry, with outpatient visits reaching 16.9407 million, a 12.14% increase, and surgical procedures totaling 1.2947 million, up 9.38% [1] Business Performance - The company’s refractive project revenue was 7.603 billion yuan, growing by 2.31%, while optical project revenue reached 5.279 billion yuan, increasing by 6.42% [1] - Cataract surgery revenue was 3.489 billion yuan, up 4.87%, and anterior segment surgery revenue was 1.898 billion yuan, growing by 5.95% [1] - Posterior segment surgery revenue amounted to 1.499 billion yuan, reflecting an 8.22% increase [1] Strategic Expansion - The company is enhancing its ophthalmology network, having established the Changsha Medical Center in 2024 to improve medical education and research capabilities [2] - Regional eye centers in Shanghai and Nanning have been completed, while facilities in Hubei, Anhui, Shenyang, and Guizhou are operational, and Beijing Aier Yingzhi is under construction [2] - The acquisition of 87 medical institutions has further strengthened the grassroots hospital network, and the company has entered the UK ophthalmology market through the acquisition of Optimax Group [2] Financial Forecast - Revenue projections for 2025-2027 are 23.681 billion, 27.084 billion, and 31.154 billion yuan, with corresponding growth rates of 12.86%, 14.37%, and 15.03% [3] - Net profit forecasts for the same period are 4.115 billion, 4.761 billion, and 5.615 billion yuan, with growth rates of 15.71%, 15.70%, and 17.95% [3] - The company is expected to maintain a strong position in the ophthalmology service sector, with a three-year CAGR of 16.45% [3]

Investment Rating - The report assigns a "Buy" rating for the company, indicating an expected price increase of over 15% in the next 6-12 months [5][12]. Core Insights - The company reported a revenue of 2.678 billion RMB in 2024, a decrease of 1.46% year-on-year, and a net profit attributable to shareholders of -102 million RMB [2]. - In Q1 2025, the company achieved a revenue of 742 million RMB, reflecting a year-on-year increase of 9.82%, with a net profit of 27 million RMB, up 61.18% year-on-year [2]. - The company is focusing on the iterative development of refractive surgery techniques and has seen stable growth in essential projects [3]. Summary by Sections Performance Review - In 2024, the company generated revenue of 2.678 billion RMB, down 1.46% year-on-year, and reported a net loss of 102 million RMB [2]. - For Q1 2025, the company recorded revenue of 742 million RMB, a 9.82% increase year-on-year, with a net profit of 27 million RMB, marking a 61.18% increase year-on-year [2]. Operational Analysis - The refractive surgery segment generated 1.227 billion RMB in revenue in 2024, down 5.31% year-on-year, with a gross margin of 47.02% [3]. - The cataract project revenue was 576 million RMB, down 3.04% year-on-year, influenced by national procurement policies [3]. - The company is introducing new technologies to enhance its competitive edge and is focusing on high-end products to mitigate the impact of price reductions [3]. Expansion Strategy - The company is implementing a "national chain + local integration" strategy, focusing on urban centers and gradually maturing new hospitals to drive future growth [4]. Profitability Forecast - The company is expected to achieve net profits of 130 million RMB, 161 million RMB, and 202 million RMB for 2025, 2026, and 2027, respectively, with corresponding EPS of 0.87, 1.07, and 1.35 RMB [5].

业绩简评 2025 年 4 月 28 日，公司发布 2024 年年度报告，24 年公司实现收 入 26.78 亿元（同比-1.46%），实现归母净利润-1.02 亿元，扣非 归母净利润-0.85 亿元。 同时公司发布 2025 年一季报，25Q1 公司实现营业收入 7.42 亿元 （同比+9.82%），归母净利润 0.27 亿元（同比+61.18%），扣非归母 净利润 0.28 亿元（同比+48.37%）。 经营分析 屈光术式迭代有望驱动增长，强刚需项目稳健增长。分业务看，屈 光项目 2024 年收入 12.27 亿元（同比下降 5.31%），毛利率 47.02% （同比下降 4.56pct）。公司持续引进蔡司全飞秒精准 4.0 等新技 术，有望进一步巩固竞争优势。白内障项目收入 5.76 亿元（同比 下降 3.04%），受人工晶体国采全面落地及 DRG/DIP 支付改革影响， 呈现"量增价减"态势。24 年白内障项目毛利率 38.93%（同比下 降 4.44pct）。公司通过引进专家、提升服务效率吸引患者，并推 广高端晶体应对集采影响。此外视光项目收入 3.86 亿元，同比下 降 2.60%；综合眼病项目收 ...